На главную
Результаты поиска “U.S. Pharmaceutical Sales Statistics” за 2018
How Trump plans to lower drug prices in US
 
08:22
Dr. Janette Nesheiwat and Heritage Foundation senior fellow Ed Haislmaier discuss why European countries are paying less for prescription drugs than the United States and how the Trump administration plans to combat this problem.
Просмотров: 4650 Fox Business
The Fines That Pharmaceutical Companies Have Paid with Gwen Olsen
 
06:00
On December 2, 2004, Gwen Olsen's niece Megan committed suicide by setting herself on fire-and ended her tortured life as a victim of the adverse effects of prescription drugs. Gwen Olsen offers an honest glimpse into alarming statistics and a health care system ranked last among nineteen industrialized nations worldwide. As a former sales representative in the pharmaceutical industry for several years, Olsen learned firsthand how an unprecedented number of lethal drugs are unleashed in the United States market, but her most heartrending education into the dangers of antidepressants would come as a victim and ultimately, as a survivor. Gwen Olsen shares one woman's unforgettable journey of faith, forgiveness, and healing. Connect with The Real Truth About Health http://www.therealtruthabouthealth.com/ https://www.facebook.com/The-Real-Truth-About-Health-467500836655781/ https://twitter.com/RTAHealth Passionate believers in whole food plant based diets, no chemicals, minimal pharmaceutical drugs, no GMO's. Fighting to stop climate change and extinction.
Просмотров: 339 The Real Truth About Health
Abilify: The Drug That Devastates Your Impulse Control Center
 
03:33
To learn more about this topic, visit http://www.levinlaw.com/america-lawyer and https://www.levinlaw.com/abilify-lawsuit-lawyer Abilify is an antipsychotic medication manufactured and marketed by Otsuka Pharmaceutical and Bristol Meyers Squibb. There are numerous lawsuits pending involving their antipsychotic medication Abilify that clearly show the drug can cause impulse issues in adults, such as chaotic gambling, shopping, binge eating and hypersexuality. America’s Lawyer Mike Papantonio discusses this. Support us by becoming a monthly patron on Patreon, and help keep progressive media alive!: https://www.patreon.com/TheRingofFire Spread the word! LIKE and SHARE this video or leave a comment to help direct attention to the stories that matter. And SUBSCRIBE to stay connected with Ring of Fire's video content! Support Ring of Fire by subscribing to our YouTube channel: https://www.youtube.com/theringoffire Be sociable! Follow us on: Facebook: http://www.facebook.com/RingofFireRadio Twitter: http://www.twitter.com/RingofFireRadio Google+: http://plus.google.com/118415831573195648557 Instagram: https://www.instagram.com/ringoffirenetwork/ Follow more of our stories at http://www.TROFIRE.com Subscribe to our podcast: http://www.ROFPodcast.com Statistics show that about 1 out of 5 American citizens suffer from some form of mental illness each year. These illnesses run the gamut from depression to Tourette’s syndrome. And with a market of more than 42 million people a year as their potential clients, Big Pharma hasn’t wasted any time creating countless pills they claim will help solve your mental health problems. There are plenty of medications available that do provide relief for people suffering from mental health problems, but there are also a wide variety of pills that have had their efficacy overstated by drug companies who were just trying to cash in on the latest blockbuster market that has opened up. Abilify is an anti-psychotic medication manufactured and marketed by Otsuka Pharmaceutical and Bristol Meyers Squibb. Its used in the treatment of schizophrenia, bipolar disorder, Tourette’s syndrome, autism and depression. It’s intended to help decrease hallucinations, disorganized thinking, mood swings, depressive thoughts and tics. It's not approved to treat symptoms related to dementia, and can increase the risk of death in patients suffering from dementia. There are numerous lawsuits pending involving their anti-psychotic medication Abilify that clearly show the drug can cause impulse issues in adults, such as chaotic gambling, shopping, binge eating and hypersexuality. And with every one of those issues comes an entirely new set of problems for the people taking it. There have been reports of people losing everything by gambling away their homes, cars, and retirement funds due to the effects of Abilify. People are wrecking their home lives because of the side effects of abilify. What is so remarkable of all that is that the science appears to be absolutely solid that abilify is at the heart of the problem. According to the lawsuits that have been filed against Otsuka and Bristol Meyers Squibb, the company was fully aware of how their medication adversely effected a person’s impulse control and they completely failed to warn the public about these dangers. Documents point to the fact that the company had plenty information to show the problems here with the side effects related to abilify. They over-sold the effectiveness of the drug because and kept quiet about the risks because they wanted a piece of the 42 million customer market. And they were wildly successful. In 2014, Abilify was one of the best-selling medications in the United States, bringing in more than $7 billion for Big Pharma. In spite of all the dangers that have been emerging in the public arena with this medication for more than 4 years, juvenile detention centers have been spending hundreds of thousands of dollars each year buying stockpiles of Abilify so they can medicate juvenile delinquents instead of rehabilitating them. And these drugs are only increasing the frequency of the very behaviors that landed these children in trouble in the first place.
Просмотров: 4545 The Ring of Fire
Big Pharmaceutical Companies Don’t Want You to KNOW this  ;) WAKE UP AND DITCH THE MEDS
 
08:52
Pharmaceutical companies spend billions of dollars marketing drugs to doctors. Those of us in the medical field have a few issues with that ;) Want to be a drug addict? If you live in the U.S. chances are you probably already are. The U.S. - land of the free, of MTV, and of legal drugs. This might just be what makes America great. A place where our doctors prescribe us pills we don’t need for conditions that don’t exist. It’s a win-win. Big Pharma gets bigger and richer and we get higher or just die. The story was different 50 years ago when Jon went down to his dentist’s office to get his wisdom teeth pulled and the doctor gave him aspirin as pain medication. This was a time when young men went to war and women worked their asses off at home to save the country from collapse. Now? We get high, play video games, watch YouTube, and complain when someone doesn’t call us the right gender. And these days if old Jonny boy goes to the dentist and wants some work done it’s dealers choice. Vicodin. Percocet. Codeine. You name it. Whatever company happens to be in bed with your doctor that day. And if you don’t have private insurance that pays for your drugs? No problem. Sign up for Medicaid. You’ll definitely be able to get free drugs through them. First what exactly is the pharmaceutical industry? To make a long story short it’s a business that creates drugs for use as medications. It’s important to note that it’s not a terrible industry. In fact they have made some very important discoveries like insulin which has saved millions of lives or the countless vaccines that have protected us from at one point, very common diseases like measles and hepatitis. The problem is not the idea of pharmaceuticals – drugs are neither good nor bad. They can either be helpful or dangerous depending on their use. The problem with big pharma is that it is literally killing people. And it’s making a profit doing so. And our government is basically encouraging it. You may ask yourself how an industry that it supposed to be providing us medication which is regulated by the Federal Drug Administration – an organization responsible for “protecting the public health by assuring the safety, efficacy and security of human…drugs,” is killing us. Let’s first look at the health statistics: • 99% of hydrocodone worldwide use is in the U.S – we know this drug more colloquially as Vicodin (which is just a company that makes hydrocodone). This is a drug that the FDA rates as less dangerous as marijuana but in 2011 caused nearly 100,000 emergency department visits. • The U.S. makes up 5% of the world’s population but consumes 80% of its opioid consumption • On average 40 deaths per day are linked to specifically prescription opioids and over 100,000 deaths per year linked with prescription drugs in general. This is far more deaths than what illegal street drugs cause. • Prescription drugs are now the 4th leading cause of death in the U.S. Ok. You get the point. Prescription drugs are dangerous and they are killing people. But now the question is why are people taking them if they’re so dangerous? The answer lies in the incredible reach of big Pharma. The pharmaceutical industry spends between 30 and 60 billion dollars a year on advertising their miracle drugs. You’ve all seen their ads – blue skies, beautiful couple, trees – having trouble sleeping? Bad knees? Buy our pill and feel like new. And then the 10 second list of possible side effects which always include “and in extreme cases, death.” The folks that regulate these advertisements have a budget of $9 million dollars. Do you really think a $9 million dollar budget is enough to regulate something that is more than 6,000 times that size. This is not a David vs. Goliath story. This is an ant vs. an elephant. Big pharma is also notorious for selling drugs that aren’t approved for certain symptoms – a practice called Off-Label Promotion. For example your doctor might prescribe you an antidepressant because she or he believes it will help your migraines. This practice is at times is legal and at others illegal. If illegal you will learn shortly that the fine usually is smaller than the profit these companies make. Big pharma might just consider it another tax of doing business. And yes it has in some cases caused death. There is also the idea that big Pharma creates new illnesses and solves them with their pills. Sounds like a conspiracy theory, right? But actually it makes a lot of sense and you’ve probably seen an ad that talks about some made up illness and a pill to fix it without thinking twice. For example restless leg syndrome. Is that really an illness? https://youtu.be/ojZn1P1CxJE
Просмотров: 18 Kris D.
TOP 10 Highest Payable JOBS IN U.S 2018 | Is There Pharmacy In That ? Pharma Guide
 
03:17
TOP 10 Highest Payable JOBS IN U.S 2018 | Is There Pharmacy In That? Pharma Guide Hi am Radhakrishna, Here am providing pharma guidance and hospital guidance for freshers. How to get Pharma Job Govt sector or private sector, How to fulfil Interview phobia, How to behave with consultancies, How to get Abroad Jobs, How to write entrance exams like MOH, DHA, HAAD, PROMETRIC, How to fulfil job experience, Pharma Industries and their job opportunities, How to survive in Pharma Industry, What is the growth in Pharma Industry? What are the features of Hospital Jobs? Here am giving an introduction to Pharma category job and their importance. ******************************************************** Pharma Guide channel is the first Indian YouTube channel to share Pharmaceutical guidance and Hospital guidance in Telugu. ********************************************************  For subscribe: goo.gl/AKbA2Y  Facebook: goo.gl/csuyjx  FB page: goo.gl/1mfKMH  Gmail: radhakrishnakotapati1481@gmail.com  Twitter: goo.gl/DhvNes  Website: http://pharmaguideradhakrishna.com/  Blog: http://pharmaguideradhakrishna.blogspot.com/  Google+: goo.gl/C2FVHR **************************************************************** #PharmaGuide #PharmaGuideRadhakrishna
Просмотров: 487 Pharma Guide
Pharma Execs BUSTED Paying Millions To Doctors To Push Deadly Drugs
 
04:18
New reports show that the Bayer Healthcare Corporation paid several million dollars spread out across thousands of doctors to push their incredibly dangerous birth control called Essure. This is a very common practice with Big Pharma, and it leaves patients without an informed choice about what medications and medical devices that they put in their bodies. Ring of Fire’s Farron Cousins discusses this. For more information on the Essure lawsuits, visit https://www.levinlaw.com/essure-lawsuit-assistance-chronic-pain-tube-puncturing   Link – https://www.cnn.com/2018/07/27/health/essure-bayer-doctor-payments-eprise/index.html?no-st=1532884597   Support us by becoming a monthly patron on Patreon, and help keep progressive media alive!: https://www.patreon.com/TheRingofFire Spread the word! LIKE and SHARE this video or leave a comment to help direct attention to the stories that matter. And SUBSCRIBE to stay connected with Ring of Fire's video content! Support Ring of Fire by subscribing to our YouTube channel: https://www.youtube.com/theringoffire Be sociable! Follow us on: Facebook: http://www.facebook.com/RingofFireRadio Twitter: http://www.twitter.com/RingofFireRadio Google+: http://plus.google.com/118415831573195648557 Instagram: https://www.instagram.com/ringoffirenetwork/ Follow more of our stories at http://www.TROFIRE.com Subscribe to our podcast: http://www.ROFPodcast.com According to a bombshell new report on CNN, doctors across the country have been paid by big pharma to prescribe you dangerous medications. Specifically, this CNN expose looked at the Bayer Healthcare Corporation, and their conduct regarding their permanent birth control method called Essure. Now, what this is, it is a small metal device that is implanted into a woman's fallopian tubes, and it's supposed to stay there forever, and prevent her from ever getting pregnant. In reality, what's happening is that little metal device is breaking apart, sending little shards of metal all through women's bodies. According to some of the people interviewed for this CNN piece, it resulted in them having hysterectomies, removing the uterus and fallopian tubes, because they were all embedded with that metal, and to remove the organs was the only way to actually get the medical device out of their body. Bayer announced last week they were taking this thing off the market, but that still doesn't excuse their behavior, and the behavior of the doctors who prescribed it because they were on the dole from Bayer Healthcare Corporation. Here's what this investigation found. Between 2013 and 2017, Bayer paid $11,850, a combined two and a half million dollars, all related to that Essure permanent birth control device. Two and a half million dollars, spread out between almost 12,000 doctors. So, yeah, some doctors got a little less, maybe a few hundred dollars, maybe a few thousand. A couple of them, though, made close to 200,000. There's this one doctor, Dr. Cindy Basinski, who got $168,000.68 from Bayer, all to promote this device that they knew was faulty. They knew it was destroying the lives of women, and yet these doctors did it anyway. According to some of the women who were interviewed in this piece, their doctors actually were very pushy about forcing them to get this device. They say they were very aggressive with it. They did not want the women to know that there were other options, other possibilities. They were being paid by Bayer, and damn it, they were going to push those Bayer devices. This is not unique to Bayer and Essure. This happens every day with medications across the board. Big pharma ... And there is a phenomenal expose on ProPublica Dollars for Docs. It started several years ago, where they document all of the money that doctors take from health care organizations. You can actually go on there and look up your own doctor. But these doctors are more likely to prescribe a medication if they have been paid by that health care company. It's simple cause and effect. Just like in political campaigns, the candidate who spends the most money typically wins, the same is true with medicine. Whichever pharma company pays the doctor the most money, they're going to be the ones that win that prescription, regardless of whether or not the drug they're given, the device they're given, is going to kill or maim or disfigure that consumer. It happens every day. The worst part about all of this is, it is 100% legal. It may be unethical, but nobody's getting in trouble for this. They can't have their medical license revoked. This is something that happens daily. Big pharma's a part of it. Too many ... well, apparently thousands upon thousands of doctors in this country are a part of it, and patients never know.
Просмотров: 7564 The Ring of Fire
The USA Has 5% Of The Worlds Population And Uses 70% Of The World's Pharmaceuticals
 
10:47
On December 2, 2004, Gwen Olsen's niece Megan committed suicide by setting herself on fire-and ended her tortured life as a victim of the adverse effects of prescription drugs. Gwen Olsen  offers an honest glimpse into alarming statistics and a health care system ranked last among nineteen industrialized nations worldwide. As a former sales representative in the pharmaceutical industry for several years, Olsen learned firsthand how an unprecedented number of lethal drugs are unleashed in the United States market, but her most heartrending education into the dangers of antidepressants would come as a victim and ultimately, as a survivor. Gwen Olsen shares one woman's unforgettable journey of faith, forgiveness, and healing. Connect with The Real Truth About Health http://www.therealtruthabouthealth.com/ https://www.facebook.com/The-Real-Truth-About-Health-467500836655781/ https://twitter.com/RTAHealth Passionate believers in whole food plant based diets, no chemicals, minimal pharmaceutical drugs, no GMO's. Fighting to stop climate change and extinction.
Просмотров: 627 The Real Truth About Health
John Ioannidis: The role of bias in nutritional research
 
41:56
John P.A. Ioannidis, C.F. Rehnborg Professor in Disease Prevention in the School of Medicine, and Professor, by Courtesy, of Statistics and Biomedical Data Science, Stanford University, presented "The role of bias in nutritional research" at the Swiss Re Institute's "Food for thought: The science and politics of nutrition" conference on 14 - 15 June 2018 in Rüschlikon. Find out more about the event: http://institute.swissre.com/events/food_for_thought_bmj.html
Просмотров: 2833 Swiss Re
Why prescription drugs are more expensive in US than overseas
 
07:02
Former Health & Human Services Secretary Michael Leavitt on why some drugs are more expensive in the U.S. than overseas.
Просмотров: 549 Fox Business
Big Pharma....
 
01:47
Big Pharmaceutical Companies Don’t Want You to KNOW this ;) WAKE UP AND DITCH THE MEDS Pharmaceutical companies spend billions of dollars marketing drugs to doctors. Those of us in the medical field have a few issues with that ;) Want to be a drug addict? If you live in the U.S. chances are you probably already are. The U.S. - land of the free, of MTV, and of legal drugs. This might just be what makes America great. A place where our doctors prescribe us pills we don’t need for conditions that don’t exist. It’s a win-win. Big Pharma gets bigger and richer and we get higher or just die. The story was different 50 years ago when Jon went down to his dentist’s office to get his wisdom teeth pulled and the doctor gave him aspirin as pain medication. This was a time when young men went to war and women worked their asses off at home to save the country from collapse. Now? We get high, play video games, watch YouTube, and complain when someone doesn’t call us the right gender. And these days if old Jonny boy goes to the dentist and wants some work done it’s dealers choice. Vicodin. Percocet. Codeine. You name it. Whatever company happens to be in bed with your doctor that day. And if you don’t have private insurance that pays for your drugs? No problem. Sign up for Medicaid. You’ll definitely be able to get free drugs through them. First what exactly is the pharmaceutical industry? To make a long story short it’s a business that creates drugs for use as medications. It’s important to note that it’s not a terrible industry. In fact they have made some very important discoveries like insulin which has saved millions of lives or the countless vaccines that have protected us from at one point, very common diseases like measles and hepatitis. The problem is not the idea of pharmaceuticals – drugs are neither good nor bad. They can either be helpful or dangerous depending on their use. The problem with big pharma is that it is literally killing people. And it’s making a profit doing so. And our government is basically encouraging it. You may ask yourself how an industry that it supposed to be providing us medication which is regulated by the Federal Drug Administration – an organization responsible for “protecting the public health by assuring the safety, efficacy and security of human…drugs,” is killing us. Let’s first look at the health statistics: • 99% of hydrocodone worldwide use is in the U.S – we know this drug more colloquially as Vicodin (which is just a company that makes hydrocodone). This is a drug that the FDA rates as less dangerous as marijuana but in 2011 caused nearly 100,000 emergency department visits. • The U.S. makes up 5% of the world’s population but consumes 80% of its opioid consumption • On average 40 deaths per day are linked to specifically prescription opioids and over 100,000 deaths per year linked with prescription drugs in general. This is far more deaths than what illegal street drugs cause. • Prescription drugs are now the 4th leading cause of death in the U.S. Ok. You get the point. Prescription drugs are dangerous and they are killing people. But now the question is why are people taking them if they’re so dangerous? The answer lies in the incredible reach of big Pharma. The pharmaceutical industry spends between 30 and 60 billion dollars a year on advertising their miracle drugs. You’ve all seen their ads – blue skies, beautiful couple, trees – having trouble sleeping? Bad knees? Buy our pill and feel like new. And then the 10 second list of possible side effects which always include “and in extreme cases, death.” The folks that regulate these advertisements have a budget of $9 million dollars. Do you really think a $9 million dollar budget is enough to regulate something that is more than 6,000 times that size. This is not a David vs. Goliath story. This is an ant vs. an elephant. Big pharma is also notorious for selling drugs that aren’t approved for certain symptoms – a practice called Off-Label Promotion. For example your doctor might prescribe you an antidepressant because she or he believes it will help your migraines. This practice is at times is legal and at others illegal. If illegal you will learn shortly that the fine usually is smaller than the profit these companies make. Big pharma might just consider it another tax of doing business. And yes it has in some cases caused death. There is also the idea that big Pharma creates new illnesses and solves them with their pills. Sounds like a conspiracy theory, right? But actually it makes a lot of sense and you’ve probably seen an ad that talks about some made up illness and a pill to fix it without thinking twice. For example restless leg syndrome. Is that really an illness? https://youtu.be/ojZn1P1CxJE Recall ~ https://www.wfmynews2.com/article/news/health/recall-of-blood-pressure-heart-failure-medications-with-cancer-causing-agent-expanded/85-581045755
Просмотров: 12 Kris D.
'Smart drugs' epidemic as one in 12 adults admit taking them - with most trying them at work
 
08:32
One in 12 adults has taken "smart drugs" - with most trying them at work, a survey shows. Neuroscientists said growing numbers of people were turning to medication in a bid to cope with workload pressures. And they warned that the pills could cause long-term damage, with little research tracking the consequences over a lifetime. "Smart drugs" are illegal to sell without a prescription in the UK, but not illegal to buy. Among the most commonly used are Adrafinil and Modafinil, which are usually prescribed to patients with sleeping disorders, along with Adderall and Ritalin, which are both stimulants primarily used to treat ADHD. The survey carried out for the Telegraph shows that 8 per cent of UK adults say they have taken the drugs to gain an intellectual "edge". While most debate about the use of medication to boost attention span, concentration and energy levels has focused on university students, the most likely place for people to try so-called "smart drugs" was at work. In total, 44 per cent of those who had tried off-label use of drugs such as Modafinil or Ritalin saying they first did so in the workplace. Read the full article here: https://www.telegraph.co.uk/news/2018/06/15/smart-drug-epidemic-one-12-adults-admit-taking-trying-work/ -- -- -- -- -- -- Get the latest headlines: http://www.telegraph.co.uk/ Subscribe: http://www.youtube.com/subscription_center?add_user=telegraphtv Like us on Facebook: http://www.facebook.com/telegraph.co.uk Follow us on Twitter: https://twitter.com/telegraph Follow us on Google+ https://plus.google.com/102891355072777008500/ Telegraph.co.uk and YouTube.com/TelegraphTV are websites of The Daily Telegraph, the UK's best-selling quality daily newspaper providing news and analysis on UK and world events, business, sport, lifestyle and culture.
Просмотров: 1851 The Telegraph
Opioid Nation: An American Epidemic
 
58:50
Opioid Nation: An American Epidemic
Просмотров: 127 KPRC 2 Click2Houston
US deal launches OptiBiotix's LPLDL probiotic into huge pharma space
 
08:42
Per Rehne, commercial director at OptiBiotix Health PLC (LON:OPTI), tells Proactive's Andrew Scott they've licensed out their cholesterol-lowering bacteria to an unnamed US company, which plans to use it to create a high-value pharmaceutical drug. Discussing some of the numbers involved, Rehne says Opti will receive a six-figure payment on the official signing of the agreement and two ‘milestone’ awards totalling seven figures. An additional six-figure amount, plus royalties on future sales, would be due if a product was launched. Furthermore they'll receive a seven-figure payment should the American business decide to exercise its option to broaden the licence agreement out to a global deal.
Просмотров: 828 Proactive Investors Stocktube
My #1 Favorite Dividend Stock of All Time (If I Could Only Own 1 Dividend Stock)
 
25:47
Several subscribers recently asked about my favorite dividend growth stock of all time. Specifically, they asked which dividend stock I would own if I had to place all of my investment funds in one single stock. My answer is quite simple, as Johnson & Johnson (ticker: JNJ) is already the largest position in my portfolio. Today's video explains why Johnson & Johnson is my favorite stock for dividends, complete with fundamental analysis. I get started with some high level thoughts. Why do I like this stock so much? It really comes down to some high level concepts including: * Predictability (and stability) * Incredible margins (gross profit and operating) * Population trends (aging US population and growing global population) * More! Next, I dive into my Johnson & Johnson fundamental stock analysis. Specifically, I discuss concepts including: * Revenue Growth: I really enjoy how revenue is up 25% comparing 2007 and 2017. I also like how revenue tends to grow predictably on a year-by-year basis. It's like clockwork. * US versus international mix. International sales are getting close to representing 50% of this company's mix. * Incredible Margins: Gross profit is at 66.8% (wow!) and operating profit is at 23% (both from the 2017 annual report). * Dividend growth: I invest for passive income and cash flow! I need to buy companies to put cash in my pocket, cash that can be used to pay the bills. Johson & Johnson is a great example, as they've raised their dividend over 105% comparing 2017 to 2007. Despite stellar fundamentals, it looks like Johnson & Johnson has a PE ratio in the 22.94 range right now (possibly a bit lower). I backed into this number, since EPS is thrown off by one-time tax items. Certainly, the stock is priced for perfection, but it always seems to be! While I'm not buying this stock in 2018 (other than reinvesting dividends), I do want to buy more. I'm waiting for a correction, although I never expect a big one with this stock. Of course, there are a few risk factors with JNJ. I close out discussing those potential risks: * Patent expiration and the need to always innovate in their pharmaceutical division. * Overall pricing of their products (the US health care system is broken). Want to learn more about my dividend growth investing strategies? Here are a few popular videos on how I would hypnotically invest different sums of money. Getting started with $1,000: https://www.youtube.com/watch?v=Iijz-5vGSh0 Getting started with $5,000 in dividend stocks: https://www.youtube.com/watch?v=5Bp0TzQKRr0 Getting started investing with $10,000: https://www.youtube.com/watch?v=4i_3KAY1ZMo Going big with $25,000 in dividend stocks: https://www.youtube.com/watch?v=CGrf5He8ieU Investing $50,000 in income-producing securities: https://www.youtube.com/watch?v=ishEcrSTK-c Want to connect on Instagram? Please make sure to say hi! https://www.instagram.com/ianlopuch/ Disclosure: I am long Johnson & Johnson (JNJ). I own this stock in my portfolio. Disclaimer: I'm not a licensed investment advisor, and today's video is just for entertainment and fun. This video is NOT investment advice. Also, I'm not a tax advisor and today's video is NOT tax advice. Please talk to your licensed investment advisor before making any financial decisions. All content on my YouTube channel is (c) Copyright IJL Productions LLC.
Просмотров: 11592 ppcian
How To Get Referrals From Closed Hospital Systems
 
10:31
"We exist to help service providers find those in need of care. Our ultimate goal is to help these providers increase their census, revenue, and PROFITS." Go to www.HomeCareMarketing.net to learn more or call us today at 848-444-9865. Having trouble getting into hospitals? You should probably just give up, right? WRONG! In this week's episode of A Drink with "The Hurricane," Steve discusses how to get referrals from hospitals even when they tell you no soliciting.  Video Transcript Dramatizations are my favorite type of Drink With a Hurricanes to do because I get a chance to show you what is happening and when everyday people watch dramatizations they're like man that happened just last week or how did you know. Trust me, I've been there. I've done it and I'm working with hundreds of people all around the world on their home care businesses. It happens everywhere. Closed hospital systems are the best referrals source that we could ever have but they are by far the most difficult to get into. And I don't have 90 minutes to go over how to get into a hospital on this episode of A Drink With the Hurricane. But what I am gonna say is because these closed hospital systems are everywhere, I want to put into realistic expectations just how long and how much effort it takes to develop a hospital. And also understand the reason why most people don't. So first and foremost, because a hospital has so much volume of patients, and every person in the hospital has a great need, everybody wants to get business from the hospital. Not just home care! Everybody is trying including assisted living, the pharmaceutical companies, medical device sales, home health companies, hospice companies, skilled nursing facilities, and the CCRCs. I mean everybody is trying to get business from the hospitals. By, in theory, a hospital supports like a hundred different businesses with the amount of volume that a hospital does business with. So every day, every company in the area, I mean even you yourselves, you are probably within 10 miles, maybe 15 miles from a hospital. Because when people go to the hospital and they come home they're going to need your services. So it makes sense that a hospital is the mecca it is the top of the food chain of all of the referrals in our community because people start there and then it filters through to everybody else. So logically it makes sense. Now because of that, they're the pinnacle and everybody else underneath there in the healthcare continuum in our area is all trying to get in there, they all have this policy if you can't come here and market because if they allowed people to come in and market every day 100, 200 marketing representatives, would show up canvassing for business. That's why they have the no-solicitation policy. That's why you can't get in there. That's why it's so hard to get in there. But you want to know something that's really interesting for my clients who get into hospitals? When you actually get into a hospital those caseworkers, those social workers in the emergency department, in the cardiology department, in the oncology department, or the neurology department, those specific, or orthopedic, those specific units that I'm just mentioning, they always say I had no idea you existed. No one ever comes here and tells us about this. Yeah, we'll give you referrals. And that's why we continue to go. That's why we got to go there again and again and again and again. Read more at https://homecaremarketing.net/how-to-get-referrals-from-closed-hospital-systems/
Просмотров: 299 Home Care Marketing by HME
Purdue Pharma’s extraordinary success story explained.
 
05:36
06/26/2018 - How a small family-owned drug company rose to a billion-dollar giant and changed the landscape of pain. Links: The Palm Beach Post's investigation: https://heroin.palmbeachpost.com/ Driving the Oxy Express: https://apps.mypalmbeachpost.com/oxyexpress/ Purdue and Oxy: https://heroin.palmbeachpost.com/purdue-pharma-plants-seeds-of-opioid-epidemic/ DEA Failure: https://heroin.palmbeachpost.com/rudy-giuliani-dea-free-flow-of-oxy/ Oxy Nation: https://heroin.palmbeachpost.com/how-florida-spread-oxycodone-across-america/ The History of Heroin: https://heroin.palmbeachpost.com/history-of-heroin/ No Methadone: https://heroin.palmbeachpost.com/methadone-clinics-florida-hinders-help-for-heroin-addiction/ Heroin Ablaze: https://heroin.palmbeachpost.com/florida-cuts-off-oxycodone-death-devastation-follow/ El Chapo: https://heroin.palmbeachpost.com/el-chapo-saw-heroin-coming-changed-his-business-model/ Flawed Numbers: https://heroin.palmbeachpost.com/how-bad-is-heroin-crisis-bad-numbers-mean-no-one-even-knows/ Deadly Switch: https://heroin.palmbeachpost.com/oxycodone-to-heroin-they-made-deadly-switch/
Просмотров: 936 PalmBeachPost
How to set your company apart from other door to door sales companies
 
07:22
http://www.d2dmillionaire.com/workwithd2d How to set your company apart from other door to door sales companies https://www.d2dmillionaire.com/how-to-set-your-company-apart-from-other-door-to-door-sales-companies/ Nowadays there are a lot of door-to-door sales companies, some good and some bad. The question is, what can your company do to set itself apart from other door-to-door sales companies? In this post we share 3 ways how your company can stand out from the others. Invest in your people and door-to-door sales team It’s great if your company is good at recruiting and it has the ability to bring on a lot of new sales reps each year, but do these sales rep stick? Unfortunately, many door-to-door sales companies just want to get a sales rep started and couldn’t care less about if they succeed or not. It’s really just a numbers game. Certainly you could just rely on sheer numbers and hope that a certain percentage of sales reps hired figure it out. However, a more sustainable method that can give your company a better reputation is to have effective sales training for your door-to-door sales reps. Investing in people within your company can be your best investment. It doesn’t just have to be in your door-to-door sales reps either. Investing in all of the people in your company makes a huge difference. Having a great door-to-door sales team is certainly essential, but if your customer service, technicians, product development, and other areas are improperly trained, it can cost you sales and business, even after the sale has been made. Focus on individual training with your door-to-door sales reps Certainly having great general training should be a foundation for building a successful door-to-door sales company, but having great individual sales training for your reps is just as important. Often you will have a few sales reps that are struggling, but they might each have their own unique reasons why. With some of these sales reps, some individualized training could be the difference in them staying out the entire season. Our team at D2D Millionaire offers individual sales evaluation training, where we have our reps submit audio and/or video of them in real-life situations so we can offer the best advice on what they need to do to improve their sales skills. We have found that real-life experiences are the best way to identify strengths and weaknesses which allows us to customize a specific game-plan for each sales rep. At D2D Millionaire we also accomplish this by keeping our sales teams smaller so our reps don’t feel like they are just a number. With smaller sales teams our sales managers have more time to help individual reps that may be struggling, as well as those who are doing well to do even better. Does your pay scale matter in door-to-door sales? Having a competitive pay scale for your door-to-door sales reps is important, but it isn’t as crucial as you may think. Often we find door-to-door sales companies that offer over-the-top compensation plans are usually lacking in other areas as a company. It’s great to get paid a lot when you make a sale, but if the product or service doesn’t deliver, you aren’t getting paid anything. Selling large volumes of accounts is great, only if the product and service side of things is excellent. A 100% commission is just 0% if your sales cancel. Great sales training, as mentioned above, can also impact sales rep earnings. Having a rock star compensation plan may help in the recruiting game, but if your sales reps aren’t producing on the doors, the compensation plan becomes irrelevant. All of this can lead into giving your company a bad reputation in the industry and hurt your business in the long-run. At D2D Millionaire, we’ve found that offering a fair compensation plan, in addition to providing the best sales training, and backing that up with a fantastic service and customer service, is the perfect recipe for sales rep success. Follow through on these 3 focus points for your door-to-door sales company and your business will flourish. If you happen to be considering a new door-to-door sales opportunity you will certainly get the best training available as a part of the D2D Millionaire Team. Learn more about becoming a part of our team here! http://www.d2dmillionaire.com/workwithd2d Facebook: www.facebook.com/d2dmillionaire/ P.S. If you haven’t done so yet, be sure to Download our Free Podcast on “How To Avoid The Top 5 Reasons Door-to-Door Sales Reps Fail” Click Here For Instant Access! http://www.d2dmillionaire.com/freepodcast Did you enjoy this post on, How to set your company apart from other door-to-door sales companies, please retweet and comment below.
Просмотров: 137 D2D Millionaire
Big Food and Big Pharma killing for profit?
 
11:11
Is Big Food and Big Pharma killing for profit? How can a lifestyle intervention be more powerful than medications? And how should the medical system change, in order to empower people to revolutionize their health? For more videos: https://www.dietdoctor.com/video
Просмотров: 5276 Diet Doctor
Halftime Report | Will 2019 be the Year of Reckoning for Sun Pharmaceuticals? | CNBC TV18
 
15:42
A glance at the Nifty Pharma index shows the wealth erosion in pharmaceutical companies has been steep. The Nifty Pharma index has lost 14% in 2018 and over 20% in the past two years with bigwig stocks such as Sun Pharmaceuticals not too far from these statistics. Sun Pharma has lost 14% of its market cap with an over 30% loss in the past two years. Like the sector, the main reasons for Sun’s underperformance is mainly two fold. CNBC-TV18 is India's No.1 Business medium and the undisputed leader in business news. The channel's benchmark coverage extends from corporate news, financial markets coverage, expert perspective on investing and management to industry verticals and beyond. CNBC-TV18 has been constantly innovating with new genres of programming that helps make business more relevant to different constituencies across India. India's most able business audience consumes CNBC-TV18 for their information & investing needs. This audience is highly diversified at one level comprising of key groups such as business leaders, professionals, retail investors, brokers and traders, intermediaries, self-employed professionals, High Net Worth individuals, students and even homemakers but shares a distinct commonality in terms of their spirit of enterprise. Subscribe to our Channel: https://goo.gl/hKwgtm Like us on Facebook: https://www.facebook.com/cnbctv18india/ Follow us on Twitter: https://twitter.com/CNBCTV18News Website: http://www.moneycontrol.com/cnbctv18/
Просмотров: 570 CNBC-TV18
Florida Sues 5 Major Drug Companies Over Opioids
 
00:33
Florida sues five major pharmaceutical companies over opioids accusing them of using deceptive marketing to boost drugs sales and misinforming and downplaying the addictive nature of the drugs.
Просмотров: 109 CBS Miami
Why to join PHARMA-STATS
 
03:10
On 5th Anniversary of PHARMA-STATS our one of the oldest student Darshak Patel shared his views from Canada.
Просмотров: 107 PHARMA -STATS
A Modest Proposal for the US Economy | Jeff Deist
 
28:34
Hosted by the Mises Institute in Nashville, Tennessee, on 14 April 2018. Special thanks to an Anonymous Donor for making this event possible. Economist Bob Murphy and commercial banking expert Carlos Lara join Jeff Deist for an unbridled look at the economy from a free-market perspective. Stock markets continue to roar, despite some recent hiccups. Unemployment and inflation, at least official unemployment and inflation, are relatively low. The job market is robust, tax cuts are in place, and a new Fed Chair promises more of the same policies. But are the underlying problems with the US economy, namely huge deficits, federal debt that is 105% of GDP, and a spendthrift Congress too much to overcome? Will Trump's economy tank, along with the stock market and your 401(k)? Is your job, industry, or portfolio at risk?
Просмотров: 4612 misesmedia
Greenville County sues pharmaceutical companies
 
03:05
Greenville County sues pharmaceutical companies.
Просмотров: 39 WSPA 7News
How to Profit and Survive During Recession
 
21:31
A recession is on the way. Sub: http://bit.ly/2oDOo9S See how to survive and thrive during times of recession. Preserve your wealth and land on your feet, by learning some of the tactics and opinions that Peter Leeds relies upon. This is part two, about how to preserve your wealth in the hard times. Below is part one of the coming stock market crash, and guaranteed recession: https://bit.ly/2MpitmP *** Pot and Marijuna Stocks https://bit.ly/2J5ibPL *** Trade War https://bit.ly/2mJbxFE *** Bitcoin and Cryptocurrencies http://bit.ly/2N1iYE0 *** Stock Market Collapse http://bit.ly/2KjthVN *** Gold and Precious Metals http://bit.ly/2KKZbHK *** Penny Stocks for Beginners http://bit.ly/2ItPyLx *** Official Peter Leeds Website http://www.PeterLeeds.com
Просмотров: 7238 Peter Leeds
What Is The Average Salary For A Sales Associate?
 
00:29
Average base salaries in (inr) retail sales associate salary, career info and top pay by location. Salary sales associate in melbourne, australia pay scale of an rv what 20 the largest retailers america their employees. Sales associates sales associate salary (india) payscale. 10 companies that pay salespeople really well forbes. Pay for this job rises steadily more experienced workers, but goes down significantly the few employees with than 20 years' experience average salary a retail sales associate is rs 201,151 per year. Data comes from 271941 real salaries collected directly employees and jobs on indeed if you are considering a sales job or career in sales, probably wondering what the average starting salary is for associate. Retail sales associate salary (india) payscale5 best paying companies for retail associates part time and career info 2017 salaries in india the united states what is average starting a associate? Cvtips representative. 20 may 2011 on average, sales representatives for wholesalers and manufacturers of technical and scientific products make $84360 in base salary and industry, employment (1), percent of industry employment, hourly mean wage, annual mean wage (2). 16 per hour but are likely to see a bump in pay with skills in field and account sales and customer relationship management what salary does a part time sales associate earn in your area? Salaries for part time sales associate vary by company. Said on glassdoor the $15k (40. Retail salespersons bureau of labor statistics. Sales associates earn an average wage of $9. 75, as determined by averaging glassdoor data for tj maxx, marshalls and homegoods 10 feb 2016 shift managers at walmart make an average base salary of just over one current sales associate in elkton, md. Best and worst jobs at walmart careerbliss. Sales representative salary sales associate in albuquerque, nm dollar general pay and job description. Data comes from 6775 real salaries collected directly employees and jobs on indeed average retail sales associate salary $50441 per year. Check salary trends and pay scale information for sales representative jobs across uk associate $24809(average). Recreational vehicles can cost tens of thousands dollars and even 25 sep 2017 average hourly wage for sales associates $8. Find all the information you need a typical day for retail sales associate may include average salary 14694 per month. General merchandise stores, 838,540, 26. The national average salary for this job title is arv sales associates sell dreams to those who want travel the united states in style. Monster a url? Q payscale research in joba sales associate earns an average salary of rs 234,116 per year. The term sales average salary for representative jobs. Most people with this job move on to other positions after 10 years in field the national average salary for a sales associate is united states these workers will be directly impacted by president barack obama's proposal increase federal
Просмотров: 54 SMART Hairstyles
The Open Mind: The Real Drug Crisis  - Katherine Eban
 
28:42
Investigative reporter Katherine Eban on the dangers of generic pharmaceutical manufacturing and a looming shortage. Taped: 03-26-2018 Premiered in May 1956, Open Mind was created and hosted by Richard D. Heffner, American historian, broadcaster, and University Professor of Communications and Public Policy at Rutgers, the State University of New Jersey. Fifty years after its first broadcast, Open Mind continues with a new host, Mr. Heffner's grandson, Alexander Heffner. Open Mind as a weekly public affairs program was designed to elicit guests' most meaningful insights into the challenges Americans face in a variety of contemporary areas of national concern. Watch more Open Mind at CUNY TV http://tv.cuny.edu/show/openmind OPEN18008
Просмотров: 220 cunytv75
Webinar: Understanding Clinical Trials Data
 
17:00
Pharmaceutical companies deal with ever increasing amounts of complex data in the pursuit of creating the next life-saving drugs and biologics. Data lakes, data warehouses, and analytic solutions alone have not significantly accelerated or decreased the cost of this research. We’ll look at a different approach to handling, transforming, and analyzing data to improve insights and reduce time-to-market. Join us for a guided tour of an approach that allows stakeholders across the drug development lifecycle to create, enrich, share, and analyze data in a more flexible, cost efficient, and scalable manner. This webinar will explore: -The key problems (and broken promises) of big data in the pharmaceutical industry - How to capture and enrich the mountains of structured, semi-structured, and unstructured data in your organization - Using AI and machine learning to augment human intelligence - An example of visualizing and exploring Clinical Trials data -------- Lucidworks' Fusion platform provides the enterprise-grade capabilities needed to design, develop, and deploy intelligent search apps - at any scale. For additional tips, check out Lucidworks blog: http://lucidworks.com/blog Need advanced search capabilities now? Download Fusion: https://lucidworks.com/download/ Join an upcoming Fusion or Solr training: https://lucidworks.com/resources/solr-training-and-consulting/ Contact Sales for a free consultation: https://lucidworks.com/company/contact/
Просмотров: 62 Lucidworks
Trading Weakness in TSLA
 
01:32
Ready to take the next step in your trading career? Start your one month, $7 trial today and join us in the trading room tomorrow! https://grfly.co/oi9 For technical analysis on Stocks, Forex, Futures, Equities, Options and Other Market Commentary, Follow Us on StockTwits and Twitter: Twitter: https://www.twitter.com/TradesWithTom https://twitter.com/TradeswithDave StockTwits: http://stocktwits.com/TradesWithTom https://stocktwits.com/bctdave
Просмотров: 105 basecamptrading
Ramesh Swaminathan Of Lupin Global Talks About Revenues From US In Q1
 
06:56
WATCH | Financial Tips With Porinju Veliyath►http://bit.ly/2IWrZz8 Subscribe To ET Now For Latest Updates On Stocks, Business, Trading | ► https://goo.gl/SEjvK3 Subscribe Now To Our Network Channels :- Times Now : http://goo.gl/U9ibPb The NewsHour Debate : http://goo.gl/LfNgFF To Stay Updated Download the Times Now App :- Android Google Play : https://goo.gl/zJhWjC Apple App Store : https://goo.gl/d7QBQZ Social Media Links :- Twitter - http://goo.gl/hA0vDt Facebook - http://goo.gl/5Lr4mC G+ - http://goo.gl/hYxrmj Website - www.etnownews.com
Просмотров: 206 ET NOW
Global Antidepressant Drugs Market: Opportunities and Forecasts (2018-2023)
 
02:01
Globally, the market for antidepressant drugs mask has been growing at a swift pace on the back of rising prevalence mental disorders, rising healthcare awareness and rising disposable incomes. Apart from these factors, rising healthcare facilities, increasing number of psychiatrist as well as surging number of hospital and clinics and burgeoning growth in Asia Pacific market is impelling growth in the market. A comprehensive research report that analyses the antidepressant drugs market and the drugs market by Class - Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Selective Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Benzodiazepines, Antipsychotics and Novel Agents, the report also assesses the sales of antidepressant drugs by sales channels - Hospital & Clinics, Retail Pharmacies, Others. A research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Antidepressant Drugs Market By Region (North America, Europe, Asia Pacific and Rest of the world) and By Country (U.S., Canada, Germany, United Kingdom, India, Japan China, Brazil, Saudi Arabia) for the historical period of 2013-2017 and forecast period of 2018-2023. According to Azoth Analytics research report “Global Antidepressant Drugs Market – Analysis By Drugs Class, By Sales Channel, By Region, By Country: Opportunities and Forecasts (2018-2023) - By Region (APAC, N. America, Europe, RoW), By Country (US, Canada, UK, Germany, China, India, Japan, Brazil, South Arabia)”, the global market is projected to display a robust growth represented by a CAGR of 3.12% during 2018 – 2023. The Selective Serotonin Reuptake Inhibitors (SSRIs) drug class has witnessed growth at a noteworthy rate over the past few years and in the forecast period on account of rising health awareness related to mental disorders particularly in developing countries including China, India, etc., rising healthcare expenditure as well as rising disposable incomes. Amongst the regions, North America accounts for the largest regional share in the global antidepressant drugs in 2017. The report titled “Global Antidepressant Drugs Market – Analysis By Drugs Class, By Sales Channel, By Region, By Country: Opportunities and Forecasts (2018-2023) - By Region (APAC, N. America, Europe, RoW), By Country (US, Canada, UK, Germany, China, India, Japan, Brazil, South Arabia)” has covered and analysed the potential of Global Antidepressant Drugs Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global antidepressant drugs market. Additionally, the report also highlights market entry strategies for various companies across the globe. A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Antidepressant Drugs Market: Analysis By Drugs Class (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Selective -Norepinephrine Reuptake Inhibitors, Monoamine Oxidase Inhibitors, Benzodiazepines, Antipsychotics and Novel Agents), By Sales Channels (Hospital & Clinics, Retail Pharmacies, Others) for the Regions (North America, Europe, Asia Pacific and Rest of the world) and for Countries (U.S., Canada , Germany, United Kingdom, India, Japan China, Brazil, Saudi Arabia). http://azothanalytics.com/report/healthcare-pharma/global-antidepressant-drugs-market-analysis-by-drugs-class-by-sales-channel-by-region-by-country-opportunities-and-forecasts-2018-2023-r15150 Contact us at: Azoth Analytics Pvt. Ltd. Tel: +91 120 4298 235 Email: azothanalytics7@gmail.com Site: http://azothanalytics.com/
Просмотров: 4 Azoth Analytics
Sweet sweet codeine: Nigeria's cough syrup crisis - BBC Africa Eye documentary
 
52:55
In Nigeria, thousands of young people are addicted to codeine cough syrup – a medicine that’s become a street drug. The Nigerian senate estimates that 3 million bottles of codeine syrup are drunk every day in just two states – Kano and Jigawa. But who makes this syrup? And who sells it to Nigeria’s students? BBC Africa Eye went undercover to investigate. Subscribe to our channel for more investigative journalism. Nothing stays hidden forever. Subscribe: http://bit.ly/subscribetoafrica Website: https://www.bbc.com/africa Facebook: https://www.facebook.com/bbcafrica/
Просмотров: 2267131 BBC News Africa
BREAKING News Out Of Big Pharma… It’s SUPER Bad
 
04:09
BREAKING News Out Of Big Pharma… It’s SUPER Bad In the United States, there are one million children under the age of six on psychiatric drugs. This number is particularly disturbing, considering the horrifying side effects and ineffectiveness of a good number of these types of harmful drugs. One in six Americans overall regularly take some type of medication in this category. However, children are now being swept up in Big Pharma’s desire to make money, not improve health. Mental health watchdog group Citizens Commission on Human Rights is drawing attention to the concerning fact that more than a million kids younger than six in our nation are currently taking these psychiatric drugs. According to Natural News, around half of these children are four to five years old and an incredible 274,804 of them are younger than a year old. That’s right: babies are being given psychiatric drugs. The number rises for toddlers aged two to three, with 370,778 kids in this category taking psychiatric drugs overall. If this isn’t horrifying to you, congratulations on your brainwashing. Data from IMS Health shows that the drug situation only gets worse as kids get older, with 4,130,340 kids aged 6 to 12 taking some type of psychiatric drug. You might be forgiven for assuming that most of these statistics are made up by kids taking ADHD drugs given how common that approach seems to be nowadays, but it really only accounts for a small portion of it, with 1,422 of those younger than a year old and just over 181,000 of those aged four to five taking ADHD drugs. –Natural News The biggest category of psychotic drugs given to children appears to be anti-anxiety drugs. Just over 227,132 babies under one-year-old and nearly 248,000 of those aged four to five take these medications. Again, babies are being given mind-altering drugs before their first birthday. But the news just gets worse from there. Experts believe these estimates are far too low and the real numbers are actually much higher, due in part to the tendency for some doctors to hand out psychiatric medications for “off-label” uses. This risky practice entails giving out a drug to treat something that it is not indicated for, and the long-term effects of such an approach are completely unknown. When adults choose to take psychiatric medication, it may be ill-advised in many cases, but it is still their choice to make. Children, on the other hand, lack the cognition to fully understand the lifelong impact of such a choice, and this essentially amounts to forced medication. We already know that many doctors have a financial incentive to get young people to start taking these drugs, but why are their parents so willing to get on board? Many of them are also taking psychiatric medications, of course. In fact, it has practically become a way of life in our nation and many people think of these meds as harmless. The side effects of these drugs are nothing to scoff at, however, with anti-anxiety, antidepressant and anti-psychotic drugs linked to heart attacks, psychosis, suicidal tendencies, diabetes, stroke, mania and sudden death. As if that weren’t bad enough, there’s also the fact that many of the high-profile public shootings in recent years were perpetrated by young people on such drugs, so not only do kids have the risk of dying when they take these meds, but they could also take out a whole classroom or movie theater with them. –Natural News Is this a war on our children perpetrated by Big Pharma and condoned by the government? Maybe. Nothing seems impossible anymore.
Просмотров: 19 BREAKING NEWS24H
How GSK Uses Data Wrangling for Clinical Trial Data to Accelerate Drug Development
 
04:45
Learn more about Data Wrangling solutions with Trifacta: https://www.trifacta.com/data-wrangling/ See how GSK uses Trifacta’s Data Wrangling solutions to accelerate drug development by putting clinical trial data into the hands of the business user. GSK gets data from hundreds of sources and needs a solution that can standardize that data to provide insights. Learn how data wrangling enables GSK to compare & transform disparate data for a stronger R&D process. Watch our video to learn more.
Просмотров: 1196 Trifacta
Introduction to Patent Protection
 
26:46
An introduction to what a patent is, what a patent protects, and how a patent is obtained in the United States. Produced by the Global Intellectual Property Academy (GIPA) of the United States Patent and Trademark Office. Learn more about GIPA: https://www.uspto.gov/gipa This video is also viewable at uspto.gov: https://rev-vbrick.uspto.gov/#/videos/1675951d-20ac-4fd9-ba11-ed96541867b8
Просмотров: 743 USPTOvideo
Nas Claims 12th Top 10 Album on Billboard 200 Chart With 'Nasir'
 
02:41
Nas Claims 12th Top 10 Album on Billboard 200 Chart With 'Nasir' Nas is back on the Billboard 200 albums chart, as his new Nasir set starts at No. 5, granting the hip-hop star his 12th top 10 effort. Nasir — released on June 15 via Mass Appeal/Def Jam Recordings — launches with 77,000 equivalent album units earned in the week ending June 21, according to Nielsen Music. Of that sum, 49,000 were in traditional album sales. The Billboard 200 chart ranks the most popular albums of the week in the U.S. based on multi-metric consumption, which includes traditional ...
Просмотров: 152 SS NEWS
Digital Pharma Europe exl AS
 
01:59
Digital Pharma Europe (exl) AS At Radisson Blu Edwardian, Heathrow For more information: https://www.eventbrite.com/e/digital-pharma-europe-exl-as-tickets-39219077316?aff=RMV DESCRIPTION ============ In an effort to provide our most diverse pharmaceutical and medical device executive mix to date, this year’s venue provides a centralized platform that is close to numerous UK pharma headquarters as well as Heathrow Airport. This will also allow for easy access to UK pharmaceuticals and medical device organizations and facilitate expedited travel time for European and US counterparts. By bringing together over 200 life-science industry marketers, you will be able to employ a roadmap for a fully digitalized enterprise — no what your core business offering is There are some exciting potential solutions on the horizon, but still many questions being asked: How will digital disruption transform the pharma business model? How can pharma leverage digital and navigate digital trends and technologies to maximise positive outcomes for patients? How can pharma generate value from digital medicine solutions? As pharma companies shift from implementing traditional products to connected solutions, companies are challenged to define and realise value from this new business model (e.g., revenue stream) that intelligent digital medicine solutions require. How can pharma engage with disruptive technologies? How can we demonstrate the value of digital for pharma products? Pharma companies are increasingly exploring the role that digital can play in demonstrating value through data, analytics, and real-world evidence. How will pharma adapt to successfully engage HCPs? As HCPs evolve in their engagement with patients and how they manage their practice, pharma companies will have to transform their HCP-engagement approach. We will explore these questions and more. Join the conversation and contribute to the advancement of digital health to improve patient outcomes and customer centricity! Reserve your seat for the 10th anniversary of the Digital Pharma Europe conference. We look forward to celebrating this milestone with you in London this May! For more information: https://www.eventbrite.com/e/digital-pharma-europe-exl-as-tickets-39219077316?aff=RMV “What Exactly Will I Learn?” ============================ Drive Optimized Marketing And Digital Operations, Launch Readiness And Marketing Capability By: Establishing product launch excellence and launch models for multiple therapeutic categories Measuring success in digital ROI and evaluating digital analytics Global digital transformation HCP user experience — user research — visualization and journey tools Enhancing commercial planning quality by increasing alignment among Marketing, Medical, Finance & Sales functions Improve the overall quality of strategic brand plans across BUs by developing a more patient-centric approach and delivering innovation in patient centricity Grow e-SOV for your brands by: ============================== Leveraging HCP portals across the globe — how to lead from strategy into deployment across high numbers of markets Digital engagement and programming for HCPs, 360 views, etc. Developing market-leading content strategy and targeting around e-mail magazines and Veeva approved e-mails Execute successful webcasts Improve handling of marketing material and increased i-detailing usage to increase rep call quality and sales The evolving tools and tactics of digital to improve patient quality of life and outcomes, e.g. AI and remote diagnostics Omnichannel optimization — identifying the optimal channel mix, timing of digital and sales visit that lead to drug adoption Optimized content production through the set up of a new asset management process Please contact the event manager Marilyn below for the following: - Discounts for registering 5 or more participants. - If your company requires a price quotation. Event Manager Contact: marilyn.b.turner(at)nyeventslist.com You can also contact us if you require a visa invitation letter, after ticket purchase. We can also provide a certificate of completion for this event if required. ---------------------------------- For more information: https://www.eventbrite.com/e/digital-pharma-europe-exl-as-tickets-39219077316?aff=RMV Eventbrite: https://www.eventbrite.com/o/event-promotions-by-new-york-events-list-11118815675 Twitter: https://twitter.com/nyeventslist Facebook: https://www.facebook.com/NewYorkEventsList New York Events List: http://nyeventslist.com/
Просмотров: 5 New York Events List
California's drug transparency law yields early surprises
 
08:23
California’s first-in-the-nation drug pricing transparency law is beginning to kick in — and to spur copycats, with Oregon’s governor last week signing a law that requires drug companies to disclose cost components they have long considered proprietary. Whether they’ll actually reduce prices is a crapshoot. California has already pried loose new numbers that may seem deja vu: Valeant, a magnet for criticism over past price boosts, is about to raise the price of a generic glaucoma medication by 63 percent, and Teva Pharmaceuticals, the world’s biggest generic drugmaker, plans a 49 percent price bump May 1 for an inhaled solution to prevent asthma attacks, according to documents obtained by POLITICO. The notifications are early results of the California law that in January began requiring drug companies to give major purchasers 60 days’ notice of significant increases. While it doesn’t directly affect prices, proponents hope that advance warnings — and mandating that manufacturers justify the increases — will generate enough public pressure to hold down prices. The wholesale price for the medications that trigger the notifications will be available to the public next year. “We’re going to be able to look at industry pricing activity in a way the public and the rest of us haven’t been able to track before,” said Jane Horvath, who heads the National Academy for State Health Policy’s Center for State Rx Drug Pricing. Other experts remain dubious. “We’ve seen massive, massive price increases, and shame has not trumped profit. After a while, people get numb to it,” said Adams Dudley, a pulmonologist and director of the University of California, San Francisco’s Center for Healthcare Value. Indeed, both Valeant and Teva have weathered these controversies before — just not in advance of an actual price hike. Valeant in 2015 raised the price of Syprine, which treats a rare disorder, to $21,000 — more than 30 times what it had been five years earlier. Teva recently introduced a “lower-cost” generic for $18,000 for a bottle of 100 pills, 28 times the 2010 brand price. Valeant then came back with an “authorized” generic for $19,000. With stories like these playing out across the country, California sees another area where it can play national leader. Gov. Jerry Brown explicitly described the transparency measure — supported by a broad coalition of insurers, employers and advocates arrayed against vehement drug industry opposition — as a model for other states when he signed it in October. Several states, including Massachusetts and Nebraska, have similar legislation pending. More than 150 bills have been introduced nationwide to address at least some aspect of prescription drug costs, according to the National Academy for State Health Policy. The industry sees California as a leader, too, and sued to stop the law. In a statement when the complaint was filed in December, the drug lobby PhRMA contended that the law illegally attempts to "dictate national health care policy" and thwart competition but declined further comment. The next set of legal filings is due Monday. Pharma trade groups also filed suit over laws in Maryland and Nevada that attempt to tackle drug prices in other ways. Oregon could be next. The sponsors of Oregon’s new transparency law say they closely watched California’s progress as they developed their own measure and felt emboldened when Sacramento passed it. But a provision in the Oregon bill that would have required advance notification of significant price increases, like California does, was negotiated out before passage. “The pharmaceutical industry doesn’t compromise on anything. They just say ‘no,’” said the bill’s primary author, state Rep. Rob Nosse. But Nosse, a Portland Democrat, is pleased: “Our version of transparency, I would argue, is a little more aggressive than what [California] did,” he said. Oregon will require drug companies to reveal research and development costs, profits, total sales, marketing outlays and other information relevant to price increases over 10 percent a year beginning in July 2019. California’s law has several key parts that will take effect this year and next. The law’s next phase begins Oct. 1, when health plans will have to report to the state the top 25 medications prescribed to their participants, which drugs cost payers the most and which experienced the largest aggregate year-over-year price increases. Starting on Jan. 1, 2019, the state is required
Просмотров: 2 NEWS HEADLINES CN1
3 STOCKS TO BUY APRIL 2018
 
09:41
3 Stocks to Buy in April 2018 is a popular series on this channel. I cover stocks to watch, buy, invest in April 2018! These are 3 stocks you can buy today, and hold forever on the dip as they are currently presenting great opportunities for entries. The 3 picks for this month are Nvidia Stock, Facebook Stock, and Home Depot Stock. All 3 of these companies have had a great 2017, and have recently been experiencing some turbulence but I believe they will make a good recovery in 2018. 1) Nvidia Stock Analysis NVDA These guys are just a profit machine and growth machine and they keep posting outstanding numbers and show no signs of slowing down. The last month or so as the market has been a bit weak and volatile, NVDA has kind stood its ground. Everytime it sells off, buyers come back in to push it higher. This stock is really outperforming the market right now, and is showing similar strength as AMZN and NFLX as well. In march, we had 2 analysts come out and reiterate their view on NVDA this month. Both have targets that are a lot higher than the current share price and it's clear analysts are also very bullish on NVDA's future. If you want to see my technical analysis and view on Nvidia, check out the video. 2) Facebook Stock Analysis FB You guys already know my stance on FB - this is a stock I personally hold in my long term portfolio, and it's a company that just keeps growing. They own FB, Insta, and WHatsapp, and they have over 2B users on these platforms. Celebs are switching from Snap to Insta, which is where I think FB will be seeing a lot of $ coming in from. The selloff imo was unwarranted - I gave my reasoning in this video so check it out if you're unsure. I believe FB will recover this year - but April in a great time to scoop up more shares in this company. It might be a slower recovery than we're used to, but as long as their earnings and growth continue, it should be back to ATH this year. In march there was only 1 analyst who came out and reiterated their stance on Facebook. If you want to see my technical analysis and view on Nvidia, check out the video. 3) Home Depot Stock Analysis HD HD - of course a home improvement store, the largest in this space in North America - and their only true competitor is Lowes - who is far behind. Morgan Stanley said the recent weakness has created a "compelling entry point" for investors. You shouldn't believe what these Analysts say, but you should pay attention to the general sentiment. Nothing has fundamentally changed in HD and they are still strong, and MS recognizes that. There are fears out there that interest rate hikes may affect home sales and renovation sales - but this is something we'll have to wait and see about. We did have hikes in the past, and home sales just kept rising QoQ, so if the last few years tells us anything, it's that people want to buy houses! In March, Loop Capital initiated coverage on HD. If you want to see my technical analysis and view on Nvidia, check out the video. Thank you for watching! Don't forget to LIKE, COMMENT and SUBSCRIBE if you haven't done so already to support the channel - it means a lot to me! Let me know what videos you would like me to cover in the future. Either way, remember to invest positively. Peace! Disclaimer: None of the stocks, options, or securities that I discuss should be taken as advice or recommendations to buy/sell/hold as I am not a financial adviser. The views and information presented in these videos is strictly for educational purposes and I will not be held liable for your gains or losses incurred due to trading, investing, or getting involved in the stock market. Follow me on Twitter: https://goo.gl/w4xsnl Follow me on Instagram: https://goo.gl/fW5rYn Equipment used for videos: Microphone: http://amzn.to/2zVpWGz Lighting Kit: http://amzn.to/2EVbL8t Camera: http://amzn.to/2HPaqgT Laptop for Editing: http://amzn.to/2EUbORQ
Просмотров: 3336 Positive Investing
Pharmakeia - Channeling Familiar Spirits Through Sorcery
 
01:35:32
Content mirrored from - Truth Happens: https://www.youtube.com/channel/UClwHnZ2Wos8_dB9uyPwlv2g | Please support these Truther channels. It won't be long before they take all real truth off the web for good. Share, Share, Share! Time Is Very Short Now! (SMHP Testimonial & why I posted this video.) I was imprisoned by heavy drug and alcohol addiction for 30 years and had many encounters with demonic spirits. I hung around people in dark places. This stuff is no joke. It gets darker and darker. Please wake up people. The demonic entities just want to use you as host bodies and take your souls. I went to drug rehab when I was 15 for 45 days but started using again within a week of leaving. I was diagnosed with manic bipolar in my twenties and went on and off of antidepressants. No man could give me a solution to my problems. Life kept getting darker and the demonic attacks more frequent. Satan told me I was no good and that Lord God did not love me. Near the end, I knew I would die high as I could not go without using all day. I prayed out to Abba Father. Please Lord save me from these evil addictions. I would blackout every time I used and didn't know if I would end up at the bottom of a pool or run over by a car. Jesus reached down and pulled me from this hell. He is my everything! You can break free from these addictions. Jesus is the chain breaker. It wasn't man that took away my chains but Jesus Christ. He supernaturally shook me to my core over a period of several weeks and my addictions were gone for good. I had a dream that I died and went before Lord God and could not speak to him because I was high on drugs. No one should have to think about this. This is a stronghold over you and people who love you. - SMHP Behold, I stand at the door, and knock: if any man hear my voice, and open the door, I will come in to him, and will sup with him, and he with me. Revelation 3:20 For He had commanded the unclean spirit to come out of the man. For it had seized him many times; and he was bound with chains and shackles and kept under guard, and yet he would break his bonds and be driven by the demon into the desert. Luke 8:29 Then they cried out to the Lord in their trouble, And He saved them out of their distresses. He brought them out of darkness and the shadow of death, And broke their chains in pieces. Psalm 107:13-14 This applies to all addictions, not just drugs and alcohol. ............................................. 2010 Pharmakeia Interview with Dr Future (SMHP is not promoting this channel. Just want to get the info out about Pharmakeia in these last days.) Do the background on Dr Future for yourselves please. ............................................. As always, pray and use discernment when educating yourselves on this content and any other on the internet for that matter. Take everything back to Gods Word for confirmation. ............................................. Watch How To Break Spiritual Strongholds - Full Armor of God https://youtu.be/dPkONf3pJbg . The beast system is here. Don't become part of it. They'll just use you and throw you away. It's all a lie. New videos are posted daily. Subscribe to our channel: http://www.youtube.com/c/ShakingMyHeadProductions ///////
Просмотров: 26362 Shaking My Head Productions
Medical Tourism Med Falicito
 
01:50
Med Falicito is a part of Medicaso Solutions Pvt Ltd Pvt. offering various services to the doctors, diagnostic centers and patients via this website. This has been launched in India with a vision to expand its presence in every country making healthcare an easily accessible and affordable service by giving patients the "Right of Ownership to Choose and Decide" who, what, where, when and how much instead of making them unwillingly accept whatever is available. Med Falicito offers a bouquet of end-to-end medical tourism services in India that are currently scattered and/or either being offered by standalone agents, hospitals or other facilitators/middlemen. From a patient or his/her family's perspective, it is quite painful and risky to travel all the way to another country for medical advice, surgical correction, organ transplant, cosmetic surgery or any type of medical-surgical help. Med Falicito understand medical expenses can be frustrating and if you don’t manage it sooner it will drain all your financial resources.This is where we can help you by ensuring that the medical procedure remain affordable and available to you. Quality, affordability and medical accessibility are the de-facto of Med Falicito Key points for our patients and future ones to come! ✅we will help you through the whole process from the beginning to the end and remember that you are not just a price quote for us, you are part of our family at Med Falicito 🏥
Просмотров: 117 Med Falicito
What Is The Average Salary For A Product Manager?
 
00:34
Percentage of monthly compensation (wherever offered) average salary for product manager in uae 26 aug 2016 their findings show managers consistently get the top offers, on. Googleusercontent search. Most people move on to other jobs if they have more than 20 years' experience in this career. Short answer salary 2 average product manager $100758 per year. Product manager salary in boston product salaries united states are managers the new software engineers? Highlights. What is the typical salary range for a product manager job in salaries united states by education, experience, location and average uk uae highest paid workers silicon valley are not software quartzhow much does survey results part 2. Search cwjobs for average uk salary data product manager jobs range in uae. Product manager salaries are based on responses gathered by built in boston from what is the salary for product role united states? The average of states. Product manager salaries are based on responses gathered by built in austin from anonymous good product managers hard to find and companies willing pay big numbers get them. 2098 product manager salaries provided anonymously by employees. This salary 9 feb 2017 per hired's global state of tech salaries, product managers bring in the highest average offers any roleTypical manager salary? Glassdoor. Product manager salaries are based on responses gathered by built in nyc from the average salary for a product austin is $110071. According to glassdoor, these are product managers' average salaries the salary for a manager in new york is $119727. Data comes from 26921 real salaries collected directly employees and jobs on product manager salaries, benefits packages, yearly bonuses, job descriptions, statistics available positions a summary of average salary information. Experience strongly influences income for this job answer is based largely on the first hand experience and by working with knowing product managers in different companies sectors. Typical product manager salary? Glassdoor. What salary the national average for a product manager is 15,77,000 in india senior salaries and job responsibilities may include managing multiple products or an entire portfolio manager, software. Software engineers were offered an average the digital product manager salary in london is 63,62121 jan 2013 part 2 of our and worklife survey managers this time looking at there 4. What is a typical product manager salary? Product manager, software salary (india) payscale. Years of experience in product average manager salary 7,33866 per year. Htm "imx0m" url? Q webcache. According to glassdoor, the average product manager in salary for a boston is $103736. Product manager salary in new york product austin show me the money manager's school. Product manager salaries in india is a product manager's salary determined by professional craft. Data comes from 868 real salaries collected directly employees and jobs on indeed 12 sep 2016 even inside the us, pay differences can amount to almost 20k per year. The average pay for a product manager, software is rs 1,420,631 per year. Co salaries product manager salary srch_ko0,15.
Просмотров: 74 SMART Hairstyles
Hedge Fund Manager Jeremy Grantham- Quant Trader with Event Driven Strategies
 
02:34
Jeremy Grantham is a British investor and co-founder and chief investment strategist of Grantham, Mayo, & van Otterloo (GMO), a Boston-based asset management firm. GMO is one of the largest managers of such funds in the world, having more than US$118 billion in assets under management as of March 2015. Grantham is regarded as a highly knowledgeable investor in various stock, bond, and commodity markets, and is particularly noted for his prediction of various bubbles. Event-driven strategies concern situations in which the underlying investment opportunity and risk are associated with an event. An event-driven investment strategy finds investment opportunities in corporate transactional events such as consolidations, acquisitions, recapitalizations, bankruptcies, and liquidations. Managers employing such a strategy capitalize on valuation inconsistencies in the market before or after such events, and take a position based on the predicted movement of the security or securities in question. Large institutional investors such as hedge funds are more likely to pursue event-driven investing strategies than traditional equity investors because they have the expertise and resources to analyze corporate transactional events for investment opportunities. Corporate transactional events generally fit into three categories: distressed securities, risk arbitrage, and special situations. Distressed securities include such events as restructurings, recapitalizations, and bankruptcies. A distressed securities investment strategy involves investing in the bonds or loans of companies facing bankruptcy or severe financial distress, when these bonds or loans are being traded at a discount to their value. Hedge fund managers pursuing the distressed debt investment strategy aim to capitalize on depressed bond prices. Hedge funds purchasing distressed debt may prevent those companies from going bankrupt, as such an acquisition deters foreclosure by banks. While event-driven investing in general tends to thrive during a bull market, distressed investing works best during a bear market. Risk arbitrage or merger arbitrage includes such events as mergers, acquisitions, liquidations, and hostile takeovers.[66] Risk arbitrage typically involves buying and selling the stocks of two or more merging companies to take advantage of market discrepancies between acquisition price and stock price. The risk element arises from the possibility that the merger or acquisition will not go ahead as planned; hedge fund managers will use research and analysis to determine if the event will take place. Special situations are events that impact the value of a company's stock, including the restructuring of a company or corporate transactions including spin-offs, share-buy-backs, security issuance/repurchase, asset sales, or other catalyst-oriented situations. To take advantage of special situations the hedge fund manager must identify an upcoming event that will increase or decrease the value of the company's equity and equity-related instruments. Other event-driven strategies include: credit arbitrage strategies, which focus on corporate fixed income securities; an activist strategy, where the fund takes large positions in companies and uses the ownership to participate in the management; a strategy based on predicting the final approval of new pharmaceutical drugs; and legal catalyst strategy, which specializes in companies involved in major lawsuits. FAIR USE NOTICE: This channel may make use of copyrighted material. This channel gains no profit from broadcasted content. In accordance with Title 17 U.S.C. Section 107, the material on this channel is offered publicly and without profit, to the public users of the internet for comment, non-profit, educational, and informational purpose. No copyright is claimed. This content is being posted here for financial educational purposes, so that investors will have a better understanding of financial markets.
Просмотров: 1311 scottab140
What Is The Average Salary For Healthcare Administration?
 
00:34
34 130 healthcare administration salaries provided anonymously by employees. The master's here are some statistics from the bureau of labor (bls) to give you an idea average earnings healthcare administrators health service managers as may 2012, had mean annual salaries with wages per hour $47. Average pay for administrators in hospitals was while those doctors' offices averaged wanting to go the extra mile, a master of science healthcare administration comes with starting salary on average year. Hospital and healthcare administration salary in oregon. Earn an average annual income of according to bureau labor statistics figures from may 2011. A healthcare administrator earns an average salary of per year. The median of as 2014, entry level health administration salaries in texas ranged between $52229 and while the average salary was found to be $97947 ohio department job family services published their annual occupational statistics report. Healthcare administration career outlook & salary. The highest paying skills associated with this job are strategic planning, program management, project people and data analysis. New england healthcare administrator salary payscale. How much does a health administrator make? . In fact, the average salary for michigan's healthcare statistics published by new york department of labor in 2014 revealed that statewide health administration professionals was data state oregon employment reveals that, as 2015, hospital and medical office administrator salaries job postings alaska are 21. New england a url? Q payscale research us job. Hospital and medical healthcare administration salary in michigan. New england what is the typical salary for someone with a healthcare how much do administrators make? Healthcare administration 5 top mba management careers outlook master public health. Six figure income level salaries in the healthcare administrative category. Masters in healthcare administration salary. Salary estimated from 26,545 employees, administrative assistance, average salary, salary distribution by getting an advanced degree in health administration, you'll be qualified for higher paying jobs that come attached with more responsibilities and a information job description any one interesting learning how to become healthcare national administration. Experience has a moderate effect on income for this job the median annual salary healthcare administration field was in may 2016, bls said. The national average salary for a healthcare administrator is in united naman mahajan says he thinks administration professionals need the mba indeed states that this position number of positions expected to grow by 22 percent between 2010 and 2020, faster than all occupations learn more about how administrators' roles have changed throughout years they are earning an yearly $106070 health care administrators u. How much does a health care administrator earn? Healthcare administration salary in texas. Browse average salary r
Просмотров: 125 SMART Hairstyles
GRINGO - Real Life Friends | Amazon Studios
 
01:45
David Oyelowo and Charlize Theron are real life friends, we promise. We even made a video to prove it. » SUBSCRIBE: http://bit.ly/AmazonStudiosSubscribe » Now in theaters! » Check out more Gringo: https://www.gringo-movie.com/ #GringoMovie About Gringo: Mild-mannered pharmaceutical company executive Harold Soyinka (David Oyelowo) takes a business trip from Chicago to Mexico with his cutthroat bosses Richard (Joel Edgerton) and Elaine (Charlize Theron). At the company’s Mexican lab, Richard orders manager Sanchez (Hernán Mendoza) to stop selling the bioengineered marijuana product Cannabax to a brutal, Beatles-loving cartel kingpin known as The Black Panther. Meanwhile, straight-arrow Harold learns he’ll be out of a job as soon as Richard and Elaine sell their newly cleaned-up company to a conglomerate. And when he turns to his wife Bonnie (Thandie Newton) back home for comfort, she confesses via Skype that she’s having an affair. Targeted by the ruthless Black Panther, who hopes to gain access to the Cannabax formula, Harold disappears before his bosses return to Chicago. A few hours later they receive a call informing them he’s been kidnapped, and his captors are demanding a $5 million ransom. Rather than pay, Richard dispatches his mercenary-turned-humanitarian brother Mitch (Sharlto Copley) to extract Harold. But even with some temporary assistance from warmhearted American tourist Sunny (Amanda Seyfried) and her drug-mule boyfriend Miles (Harry Treadaway), Harold’s prospects for survival grow dimmer by the minute. Pursued by an army of attackers, Harold crosses the line from mild-mannered citizen to wanted criminal. But is he out of his depth? Or two steps ahead? An action-comedy roller-coaster ride brimming with black humor, white-knuckle car chases and double-dealing, Gringo takes the concept of adventure travel to a whole new level. Directed by Nash Edgerton, who made his feature-length directorial debut with the acclaimed Australian thriller The Square, Gringo is written by Anthony Tambakis and Matthew Stone and produced by Rebecca Yeldham, Nash Edgerton, Beth Kono, A.J. Dix, Theron and Tambakis. Get More from Amazon Studios: Official site: http://bit.ly/GetMoreAmazonStudios Facebook: http://bit.ly/AmazonStudiosFacebook Twitter: http://bit.ly/AmazonStudiosTwitter Instagram: http://bit.ly/AmazonStudiosInstagram About Amazon Studios: The goal of Amazon Studios is to turn original stories into great entertainment. GRINGO - Real Life Friends | Amazon Studios https://youtu.be/F3SFvgi1EEE Amazon Studios https://www.youtube.com/AmazonStudios
Просмотров: 425 Amazon Studios
Candela Pharmacy Retail Software Demo
 
01:28
Candela Pharmacy Software helps pharmacy retailers manage stock in both packs and units, return stock to suppliers, manage batch numbers and expiry dates, substitutes generic medicines, create Manufacture wise purchase orders, handle controlled drug and maintain control drug register, and much more. Call 111 290 290 to book a demo. For more details visit: http://candelapharmacy.com/
Просмотров: 200 Retail Talk
How to Calculate Mean Kinetic Temperature in Excel Sheet?
 
01:21
Here's how you can calculate Mean Kinetic Temperature in Excel Sheet? First Download the Excel sheet: https://store.vackerglobal.com/mean-kinetic-temperature-mkt-excel-sheet The MKT excel sheet will give you the mean kinetic value, maximum and minimum values and the average and can be used for temperature sensitive products. The Mean Kinetic Calculation is widely used in pharmaceutical industries. You can calculate in Fahrenheit as well. This Video explains all the information regarding Kinetic Theory and temperature, kinetic interpretation of temperature, kinetic energy, mean temperature, how to calculate mean kinetic temperature, mkt calculation, how to calculate mkt in excel, what is mkt, mkt calculation for pharma industry, excel mkt calculation. *** Transcript This video explains how to calculate Mean Kinetic Temperature in Microsoft excel. Upon opening the Excel file, please Enable Macros. There are two sheets, one for Degree Centigrade and another one for Fahrenheit. You have to simply insert the data into these rows. You can add or delete any number of rows or columns. Now copy the data from the data logger into these columns. I have a sample data stored separately. Insert as many rows as you want. Copy the data into these columns. Delete any empty rows. Now you can see the Mean Kinetic Temperature value, Maximum and Minimum values and the average. You can do a similar method for data in Fahrenheit as well. The formula used in =M K T ( ). Please go to our stores to download this MKT calculation tool. Also, contact us for Temperature mapping study, data loggers, construction of cold rooms, dehumidification solutions etc. for Cold Chain applications. *** Contact details: Vacker LLC 306, RKM Building, Ittihad Road, Hor Al Anz Deira, Dubai Tel: +971 42 66 11 44 Email : sales.uae@vackerglobal.com Group websites: http://www.sensorsuae.com/ https://www.vackergroup.ae/ https://www.temperaturemonitoringuae.com
Просмотров: 1580 Vacker Global
STOCK ANALYSIS OF ASHOK LEYLAND 400% RETURNS
 
04:26
SM Investor Be smart in Life For more such interesting and informative updates you can also connect to us on Facebook :- https://www.facebook.com/SMInvestor1 Twitter :- https://twitter.com/sm_investor WhatsApp group: https://chat.whatsapp.com/8JzShVIapOq5PRRpOnpLM4 This Channel Covers Various Stocks/Share/Pick/Tips,Sector,IPO,Experts,etc. see below for details. Stocks Covered: Nifty 50 Stocks: Tata Consultancy Services Ltd.(TCS),Reliance Industries Ltd.(RIL),HDFC Bank Ltd.,ITC Ltd., Hindustan Unilever Ltd.(HUL),Housing Development Finance Corporation Ltd.,Maruti Suzuki India Ltd., Infosys Ltd.,Oil & Natural Gas Corporation Ltd.(ONGC),Kotak Mahindra Bank Ltd.,State Bank Of India(SBI), Larsen & Toubro Ltd.(L&T), Coal India Ltd., ICICI Bank Ltd., Bharti Airtel Ltd., Indian Oil Corporation Ltd.(IOC), HCL Technologies Ltd., NTPC Ltd., Wipro Ltd., Axis Bank Ltd., Sun Pharmaceutical Industries Ltd., Vedanta Ltd., Ultratech Cement Ltd., Asian Paints Ltd., Indusind Bank Ltd., Bajaj Finance Ltd., Power Grid Corporation Of India Ltd., Mahindra & Mahindra Ltd.(M&M), Tata Motors Ltd., Eicher Motors Ltd., Titan Company Ltd., Bajaj Finserv Ltd., Bajaj Auto Ltd., Bharat Petroleum Corporation Ltd.(BPCL), Adani Ports and Special Economic Zone Ltd., Hero motocorp Ltd., GAIL (India) Ltd., Tata Steel Ltd., Grasim Industries Ltd., Yes Bank Ltd., Tech Mahindra Ltd., Bharti Infratel Ltd., Hindalco Industries Ltd., Indiabulls Housing Finance Ltd., Zee Entertainment Enterprises Ltd., Cipla Ltd., Hindustan Petroleum Corporation Ltd.(HPCL), UPL Ltd., Lupin Ltd., Dr. Reddys Laboratories Ltd. Other stocks Covered: Dewan Housing (DHFL), Advance Enzymes, CDSL, MCX, ION Exchange, Greenply, NBCC, Godrej Agrovet, Cochin Shipyard, Sterlite Technologies, Natco Pharma, GSFC, Tata Chemicals, Ashok Leyland, Aditya Birla Capital(AB Capital), Karnataka Bank, Thomas Cook, KEC International, SCI, Uflex, Capital First, ICICI Prudential, ICICI Lombard, HDFC Life, SBI Life, Bharat Dynamics, HAL, DMART(Avenue Supermart), BSE, Bandhan Bank, Sandhar Tech, Amara Raja Batt, CARE, GIC, Force Motors, Sintex Plastics, Sintex Ind, Galaxy Surfactant, Mishra Dhatu, PC Jewelers, Fortis Healthcare, Suzlon Energy, CEAT, Idea Cellular, Titan, Bata India, Mindtree, MRF, Dabur India, Astec Lifesciences, Ruchi Soya, Bhushan Steel, Jaypee Infra, Gitanjali Gems, Kwality, Century Textile, Bliss GVS Pharma, IOL Chemicals & Pharma Sector Covered: Financials, Utilities, Consumer, Energy, Healthcare, Industrials, Technology, Telecom, Real Estate, Automotive, Auto - 2 & 3 Wheelers, Cement & Construction, Chemicals, Engineering & Capital Goods, Food & Beverages, Manufacturing, Media & Entertainment, Metals & Mining, Oil & Gas, Tobacco Type of Stocks Covered: Large cap, Mid cap, Small Cap, Multibagger, Penny, High Return, High Growth, Blue Chip Share, Debtfree, Dividend Yielding, Strong Fundamental, Profitable Business/Company Types of Trading: Intraday, Long term, Mid term, Short term, Swing Trading, F&O, IPO, Type of Calls: Jackpot, Multibagger, Value Pick, Top Recommendations, Crorepati Stocks, Latest Call Terms Covered: Candlestick Patterns, Health, Insurance, Premium, Claim, Home, Loan, Interest, Delivery Percentage, Case Study, RHP, DRHP, MACD, Candle, Gap up, Gap down, Subscribe, FII, NII, QIB, Allotment, Check, KYC, Know your company, Listing Gain, Balance Sheet, Profit & Loss, Target, Price, Bonus, Dividend, Split, Buyback, OFS, IPO, Results Q1, Q2, Q3, Q4, QoQ, YoY, Demerger, Merger Mutual Fund: Holding, Types of Mutual Fund, Best Performing MF, Worst Performing MF Channel/Site Covered: Zee Business, CNBC Awaaz, Money Control Shows Covered: Stock Fatafat Sauda Aapka, Kal Ka Bazaar, Bazaar Agle Hafte, Value Pick Kal Ka Bazaar, Market ka Punchnama Expert Covered: DD sharma, SP Tulsian, Rakesh Jhunjhunwala, Anil Singhvi, Radhakrishna Damani, Raamdeo Agarwal, TS Harihar, Sidharth Sedani, Mehraboon Irani, VK Sharma, Kunal Saraogi, Avinash Gorakshkar, Ramesh Damani, Parag Parikh, Chandrakant Sampat, Chandresh Nigam, Chaitanya Dalmia, Ashish Dhawan, Sanjay Bakshi, Samir Arora, Saurabh Mukherjea, Anoop Bhaskar, Ridham Desai, Ashwani Gujral, Sudarshan Sukhani, Prakash Gaba, Porinju Veliyath, Sandeep Jain, Dolly Khanna, Sudip Bandyopadhyay, Vijay Chopra, Sandip Jain, Sandeep Jain, Rakesh Bansal, Simi Bhaumik Broker Covered: Motilal Oswal, IIFL, Share khan, Kotak Securities, HDFC Securities, ICICI Securities, Axis Direct, Edelweiss, Geojit, Dolat Capital, Prabhudas Lilladher, Nomura, Jefferies, Languages: English, Hindi, Gujarati Date: 01, 02, 03, 04, 05, 06, 07, 08, 09, 10, 11 ,12, 13, 4, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,31 Month: January, February, March, April, May, June, July, August, September, October, November, December Year: 2017,2018,2019,2020
Просмотров: 3145 SM Investor
Empire Files  Death & Biostitutes   The US Opioid Crisis
 
21:57
https://www.telesurtv.net/english/news/Empire-Files-Abby-Martin-Talks-US-Opioid-Crisis-With-Mike-Papantonio-20171130-0017.html In 2016, 64,000 people died from drug overdoses in the United States, with roughly 80 percent of those deaths connected to opioids, according to a new report. The level of addiction has increased by almost 500 percent over the last six years. RELATED: Critics Say Trump's Opioid Epidemic Plan Is 'Counteractive' However, the question hanging on every concerned parent’s lips is where so many people could possible access that amount of drugs. Attorney Mike Papantonio believes the answer is as close as neighborhood clinics. In an exclusive interview with Abby Martin, the law professional — who made his name with triumphant lawsuits against big tobacco, chemical corporations and more — said he plans to take the United States' opioid crisis by the horns. Statistics show that 95 percent of suboxone sold in the world is sold in the United States and that one week of opioid use is enough to kick-start a severe addiction. With support from major distributors, pharmaceutical producers like Purdue Pharma were able to get their products into every hospital in the nation. Cleverly-crafted informative pamphlets describing addiction-free painkillers as well as pressure from federal health departments for critics was all it took to introduce dangerous substances such as Oxycodone into a patient’s daily prescription. Papantonio said that companies like Purdue are not the only corporations at fault. Major distributors like McKesson, Cardinal Health and AmerisourceBergen kept the lie alive when training new doctors. These distributors specifically targeted the nation’s poorer areas, former industrial towns with high unemployment, like Detroit, and poverty-stricken mining sectors in West Virginia. “They had done their homework and they figured out if somebody’s out of a job or somebody’s moved from the middle class to barely staying alive, that there’s despair that follows," he said, adding that investigations show that these sections are booming with distributors. The lawyer pointed to the growing number of sales, saying that in a town with a population of three million, distributors might sell as many as 700 million opioids. The addiction rate in these lower-class sectors has rocketed, transforming what began as a US$500 billion company into a US$500 billion industry almost overnight. “What they did, is they made this addiction issue part of their business plan,” Papantonio said. "They internalized what was happening out there on the street to become part of their business." He added that opioids then become a gateway drug for heroin. The pattern between former distribution hubs and spikes in heroin overdose admittances provide ample proof. “People ask me all the time, ‘Well, is this bigger than tobacco?’ This is much bigger than tobacco. This targeted our children,” Papantonio said. Although medical professionals are now taking action, the damage has already been done and only taking down these major corporations will make a difference for future generations, he added. RELATED: Cherokee Nation Sues Drug Firms over Opioid Crisis “My goal and what I’m doing nationally, I want to get all these cities and states, I want to get their money back for them, but I really want to make sure that some of them (corporate leaders) go to prison.” Papantonio explained that if they’re caught, the only regulation in place able to punish a corporation is the 1970s-era Substance Act, which only requires companies pay a fine for misdemeanors. Frequently, however, these same corporations will turn around and write off the fine as a business expense, leaving the federal government and taxpayers to “flip the bill.” The attorney said he’s hoping to take these companies to court with separate cases for each entity, adding that unlike other lawyers before him, he has no intention of settling. In the past, attorney generals have walked away from their cases after a US$50-$100 million settlement, a menial sum to a major corporation. “Yeah, they wear Armani suits and they have Rolex watches and they drive Bentley’s around. They come from great schools and live in Hamptons, and so we don’t look at them like criminals, so we don’t put them in prison.”
Просмотров: 302 Questioning Everything to Find Truth
Robert Califf: "Observations on Technology Enabled Healthcare" | Talks at Google
 
53:37
One of the most prominent and influential physician-scientists in the US, Robert Califf, MD served as President Obama's Commissioner of the Food and Drug Administration (FDA), responsible for protecting public health by assuring the safety and effectiveness of drugs and medical devices. Described as *“the most qualified commissioner in FDA's History”, *Dr. Califf is a cardiologist and professor of medicine at Duke University and Stanford University, with more than 1,200 publications in the peer-reviewed literature. A member of the Verily (Google Life Sciences) Scientific Board, Dr. Califf, shares his views on the nascent field of technology-enabled healthcare, in an interview with Paul Varghese, Verily's Head of Health Informatics. Moderated by Paul Varghese, MD MMSc, Head of Health Informatics, Verily Life Sciences
Просмотров: 1637 Talks at Google
California's drug transparency law yields early surprises
 
03:29
California’s first-in-the-nation drug pricing transparency law is beginning to kick in — and to spur copycats, with Oregon’s governor last week signing a law that requires drug companies to disclose cost components they have long considered proprietary. Whether they’ll actually reduce prices is a crapshoot. California has already pried loose new numbers that may seem deja vu: Valeant, a magnet for criticism over past price boosts, is about to raise the price of a generic glaucoma medication by 63 percent, and Teva Pharmaceuticals, the world’s biggest generic drugmaker, plans a 49 percent price bump May 1 for an inhaled solution to prevent asthma attacks, according to documents obtained by POLITICO. The notifications are early results of the California law that in January began requiring drug companies to give major purchasers 60 days’ notice of significant increases. While it doesn’t directly affect prices, proponents hope that advance warnings — and mandating that manufacturers justify the increases — will generate enough public pressure to hold down prices. The wholesale price for the medications that trigger the notifications will be available to the public next year. “We’re going to be able to look at industry pricing activity in a way the public and the rest of us haven’t been able to track before,” said Jane Horvath, who heads the National Academy for State Health Policy’s Center for State Rx Drug Pricing. Other experts remain dubious. “We’ve seen massive, massive price increases, and shame has not trumped profit. After a while, people get numb to it,” said Adams Dudley, a pulmonologist and director of the University of California, San Francisco’s Center for Healthcare Value. Indeed, both Valeant and Teva have weathered these controversies before — just not in advance of an actual price hike. Valeant in 2015 raised the price of Syprine, which treats a rare disorder, to $21,000 — more than 30 times what it had been five years earlier. Teva recently introduced a “lower-cost” generic for $18,000 for a bottle of 100 pills, 28 times the 2010 brand price. Valeant then came back with an “authorized” generic for $19,000. With stories like these playing out across the country, California sees another area where it can play national leader. Gov. Jerry Brown explicitly described the transparency measure — supported by a broad coalition of insurers, employers and advocates arrayed against vehement drug industry opposition — as a model for other states when he signed it in October. Several states, including Massachusetts and Nebraska, have similar legislation pending. More than 150 bills have been introduced nationwide to address at least some aspect of prescription drug costs, according to the National Academy for State Health Policy. The industry sees California as a leader, too, and sued to stop the law. In a statement when the complaint was filed in December, the drug lobby PhRMA contended that the law illegally attempts to "dictate national health care policy" and thwart competition but declined further comment. The next set of legal filings is due Monday. Pharma trade groups also filed suit over laws in Maryland and Nevada that attempt to tackle drug prices in other ways. Oregon could be next. The sponsors of Oregon’s new transparency law say they closely watched California’s progress as they developed their own measure and felt emboldened when Sacramento passed it. But a provision in the Oregon bill that would have required advance notification of significant price increases, like California does, was negotiated out before passage. “The pharmaceutical industry doesn’t compromise on anything. They just say ‘no,’” said the bill’s primary author, state Rep. Rob Nosse. But Nosse, a Portland Democrat, is pleased: “Our version of transparency, I would argue, is a little more aggressive than what [California] did,” he said. Oregon will require drug companies to reveal research and development costs, profits, total sales, marketing outlays and other information relevant to price increases over 10 percent a year beginning in July 2019. California’s law has several key parts that will take effect this year and next. The law’s next phase begins Oct. 1, when health plans will have to report to the state the top 25 medications prescribed to their participants, which drugs cost payers the most and which experienced the largest aggregate year-over-year price increases. Starting on Jan. 1, 2019, the state is required to launch a public database of those price increases. Advance notification of wholesale acquisition costs — basically drugmakers’ list prices for direct purchasers — was the first part to take effect. Most of the increases reported to major purchasers were under 10 percent, although the law requires notice only of jumps exceeding 16 percent over two years. Health care inflation overall has been running under 2 percent annually in recent years. The two largest increases in the documents made a
Просмотров: 9 NEWS HEADLINES CN1